Unconventional screening approaches for antibiotic discovery

Annals of the New York Academy of Sciences

Volumn 1354, Issue 1, 2015, Pages 54-66

  Farha, Maya A ^a   Brown, Eric D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antibiotic discovery; High throughput screening; Unconventional methodologies

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ARTICLE; CELL SCREENING; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HOST; NONHUMAN; WHOLE CELL; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTIONS; BACTERIUM; CLASSIFICATION; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84945472787     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12803     Document Type: Article

References (99)

1. Laxminarayan, R., et al. 2013. Antibiotic resistance-the need for global solutions. Lancet Infect. Dis 13: 1057-1098.
2. Silver, L.L. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24: 71-109.
3. Barker, C.A., M.A. Farha & E.D. Brown . 2010. Chemical genomic approaches to study model microbes. Chem. Biol. 17: 624-632.
4. Kitano, H. 2002. Systems biology: a brief overview. Science 295: 1662-1664.
5. Ideker, T., T. Galitski & L. Hood . 2001. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2: 343-372.
6. Swinney, D.C. & J. Anthony . 2011. How were new medicines discovered? Nat. Rev. Drug Discov. 10: 507-519.
7. Livermore, D.M. 2011. Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother. 66: 1941-1944.
8. Hart, C.P. 2005. Finding the target after screening the phenotype. Drug Discov. Today 10: 513-519.
9. Testa, C.A. & L.J. Johnson . 2012. A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents. Antimicrob. Agents Chemother. 56: 4906-4913.
10. Wang, H., et al. 2013. Discovery of wall teichoic acid inhibitors as potential anti-MRSA beta-lactam combination agents. Chem. Biol. 20: 272-284.
11. Fan, J., et al. 2014. A novel high-throughput cell-based assay aimed at identifying inhibitors of DNA metabolism in bacteria. Antimicrob. Agents Chemother. 58: 7264-7272.
12. Czarny, T.L., et al. 2014. Discovery of novel cell wall-active compounds using P ywaC, a sensitive reporter of cell wall stress, in the model gram-positive bacterium Bacillus subtilis. Antimicrob. Agents Chemother. 58: 3261-3269.
13. Navarro, G., et al. 2014. Image-based 384-well high-throughput screening method for the discovery of skyllamycins A to C as biofilm inhibitors and inducers of biofilm detachment in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 58: 1092-1099.
14. Peach, K.C., et al. 2011. An image-based 384-well high-throughput screening method for the discovery of biofilm inhibitors in Vibrio cholerae. Mol. Biosyst. 7: 1176-1184.
15. Stokes, J.M., et al. 2014. Discovery of a small molecule that inhibits bacterial ribosome biogenesis. eLife. 3: e03574.
16. Falconer, S.B., et al. 2014. Metal-induced isomerization yields an intracellular chelator that disrupts bacterial iron homeostasis. Chem. Biol. 21: 136-145.
17. Alksne, L.E., et al. 2000. Identification and analysis of bacterial protein secretion inhibitors utilizing a SecA-LacZ reporter fusion system. Antimicrob. Agents Chemother. 44: 1418-1427.
18. Crowther, G.J., et al. 2012. A mechanism-based whole-cell screening assay to identify inhibitors of protein export in Escherichia coli by the Sec pathway. J. Biomol. Screen. 17: 535-541.
19. Felise, H.B., et al. 2008. An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4: 325-336.
20. Donald, R.G., et al. 2009. A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chem. Biol. 16: 826-836.
21. Lee, S.H., et al. 2011. Antagonism of chemical genetic interaction networks resensitize MRSA to beta-lactam antibiotics. Chem. Biol. 18: 1379-1389.
22. Forsyth, R.A., et al. 2002. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43: 1387-1400.
23. Ji, Y., et al. 2001. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293: 2266-2269.
24. Huber, J., et al. 2009. Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol. 16: 837-848.
25. Wang, J., et al. 2006. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
26. Young, K., et al. 2006. Discovery of FabH/FabF inhibitors from natural products. Antimicrob. Agents. Chemother. 50: 519-526.
27. Payne, D.J., et al. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6: 29-40.
28. Chan, J.N., C. Nislow & A. Emili . 2010. Recent advances and method development for drug target identification. Trends Pharmacol. Sci. 31: 82-88.
29. Luo, H., et al. 2014. DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res. 42: D574-580.
30. D'Elia, M.A., M.P. Pereira & E.D. Brown . 2009. Are essential genes really essential? Trends Microbiol. 17: 433-438.
31. Joyce, A.R., et al. 2006. Experimental and computational assessment of conditionally essential genes inEscherichia coli. J. Bacteriol. 188: 8259-8271.
32. vanOpijnen, T. & A. Camilli . 2012. A fine scale phenotype-genotype virulence map of a bacterial pathogen. Genome Res. 22: 2541-2551.
33. Sassetti, C.M. & E.J. Rubin . 2003. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. U.S.A. 100: 12989-12994.
34. Turner, K.H., et al. 2014. Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection. PLoS Genet. 10: e1004518.
35. Umland, T.C., et al. 2012. In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media. mBio. 3: pii: e00113-12.
36. Zhang, Y.J., et al. 2013. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155: 1296-1308.
37. Murima, P., J.D. McKinney & K. Pethe . 2014. Targeting bacterial central metabolism for drug development. Chem. Biol. 21: 1423-1432.
38. Fahnoe, K.C., et al. 2012. Non-traditional antibacterial screening approaches for the identification of novel inhibitors of the glyoxylate shunt in gram-negative pathogens. PLoS One 7: e51732.
39. Zlitni, S., L.F. Ferruccio & E.D. Brown . 2013. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation. Nat. Chem. Biol. 9: 796-804.
40. Brown, S.A., K.L. Palmer & M. Whiteley . 2008. Revisiting the host as a growth medium. Nat. Rev. Microbiol. 6: 657-666.
41. Pethe, K., et al. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1: 57.
42. Spellberg, B. 2014. The future of antibiotics. Crit. Care 18: 228.
43. Keller, T.H., A. Pichota & Z. Yin . 2006. A practical view of 'druggability'. Curr. Opin. Chem. Biol. 10: 357-361.
44. Lewis, K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5: 48-56.
45. Galli, J., et al. 2007. Recurrent upper airway infections and bacterial biofilms. J. Laryngol. Otol. 121: 341-344.
46. Hurdle, J.G., et al. 2011. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat. Rev. Microbiol. 9: 62-75.
47. Boshoff, H.I. & C.E. Barry, 3rd. 2005. Tuberculosis-metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 3: 70-80.
48. Zhang, Y. & D. Mitchison . 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7: 6-21.
49. Zhang, Y., et al. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52: 790-795.
50. Shi, W., et al. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333: 1630-1632.
51. Zumla, A., P. Nahid & S.T. Cole . 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12: 388-404.
52. Andries, K., et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
53. Zhang, Y., W.W. Yew & M.R. Barer . 2012. Targeting persisters for tuberculosis control. Antimicrob. Agents Chemother. 56: 2223-2230.
54. Mak, P.A., et al. 2012. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol. 7: 1190-1197.
55. Grant, S.S., et al. 2013. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem. Biol. 8: 2224-2234.
56. Cho, S.H., et al. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51: 1380-1385.
57. deCarvalho, L.P., et al. 2009. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52: 5789-5792.
58. Byrne, S.T., et al. 2007. Pyrrolidine dithiocarbamate and diethyldithiocarbamate are active against growing and nongrowing persister Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 51: 4495-4497.
59. Hu, Y., et al. 2010. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS One. 5: e11818.
60. Kim, J.S., et al. 2011. Selective killing of bacterial persisters by a single chemical compound without affecting normal antibiotic-sensitive cells. Antimicrob. Agents. Chemother. 55: 5380-5383.
61. Hu, Y., A.R. Coates & D.A. Mitchison . 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 47: 653-657.
62. Grant, S.S., et al. 2012. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc. Natl. Acad. Sci. U.S.A. 109: 12147-12152.
63. Allison, K.R., M.P. Brynildsen & J.J. Collins . 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473: 216-220.
64. Farha, M.A., et al. 2013. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem. Biol. 20: 1168-1178.
65. Prakash Singh, M. 2006. Rapid test for distinguishing membrane-active antibacterial agents. J. Microbiol. Methods. 67: 125-130.
66. Lacriola, C.J., S.P. Falk & B. Weisblum . 2013. Screen for agents that induce autolysis in Bacillus subtilis. Antimicrob. Agents. Chemother. 57: 229-234.
67. Mascio, C.T., J.D. Alder & J.A. Silverman . 2007. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents. Chemother. 51: 4255-4260.
68. Stanley, S.A., et al. 2014. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10: e1003946.
69. Stanley, S.A., et al. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7: 1377-1384.
70. Jayamani, E., et al. 2015. Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model. Antimicrob. Agents Chemother. 59: 1728-1737.
71. Moy, T.I., et al. 2006. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. U.S.A. 103: 10414-10419.
72. Moy, T.I., et al. 2009. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol. 4: 527-533.
73. Takaki, K., et al. 2012. An in vivo platform for rapid high-throughput antitubercular drug discovery. Cell Rep. 2: 175-184.
74. Slater, L.H., et al. 2013. Identification of novel host-targeted compounds that protect from anthrax lethal toxin-induced cell death. ACS Chem. Biol. 8: 812-822.
75. Tam, J., et al. 2015. Small molecule inhibitors of clostridium difficile toxin b-induced cellular damage. Chem. Biol. 22: 175-185.
76. Christophe, T., et al. 2009. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5: e1000645.
77. Pethe, K., et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19: 1157-1160.
78. MacRae, C.A. & R.T. Peterson . 2003. Zebrafish-based small molecule discovery. Chem. Biol. 10: 901-908.
79. Hamamoto, H., et al. 2015. Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat. Chem. Biol. 11: 127-133.
80. Trede, N.S., et al. 2004. The use of zebrafish to understand immunity. Immunity 20: 367-379.
81. Clatworthy, A.E., et al. 2009. Pseudomonas aeruginosa infection of zebrafish involves both host and pathogen determinants. Infect. Immun. 77: 1293-1303.
82. Torraca, V., et al. 2014. Macrophage-pathogen interactions in infectious diseases: new therapeutic insights from the zebrafish host model. Dis. Model Mech. 7: 785-797.
83. Meijer, A.H. & H.P. Spaink . 2011. Host-pathogen interactions made transparent with the zebrafish model. Curr. Drug Targets 12: 1000-1017.
84. Keith, C.T., A.A. Borisy & B.R. Stockwell . 2005. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4: 71-78.
85. Fitzgerald, J.B., et al. 2006. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2: 458-466.
86. Zimmermann, G.R., J. Lehar & C.T. Keith . 2007. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12: 34-42.
87. Dancey, J.E. & H.X. Chen . 2006. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 5: 649-659.
88. Millan, M.J. 2006. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther. 110: 135-370.
89. Borisy, A.A., et al. 2003. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U.S.A. 100: 7977-7982.
90. Ramon-Garcia, S., et al. 2011. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob. Agents Chemother. 55: 3861-3869.
91. Taylor, P.L., et al. 2012. A forward chemical screen identifies antibiotic adjuvants in Escherichia coli. ACS Chem. Biol. 7: 1547-1555.
92. Farha, M.A., et al. 2013. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to beta-lactams. ACS Chem. Biol. 8: 226-233.
93. King, A.M., et al. 2014. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature 510: 503-506.
94. Ejim, L., et al. 2011. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7: 348-350.
95. Wood, K., et al. 2012. Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proc. Natl. Acad. Sci. U.S.A. 109: 12254-12259.
96. Lehar, J., et al. 2007. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 3: 80.
97. Folger, O., et al. 2011. Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol. 7: 501.
98. Zhao, X.M., et al. 2011. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput. Biol. 7: e1002323.
99. Guimera, R. & M. Sales-Pardo . 2013. A network inference method for large-scale unsupervised identification of novel drug-drug interactions. PLoS Comput. Biol. 9: e1003374.